From interference to insight: pseudo-lipidemia led to the diagnosis of Waldenström macroglobulinemia.

BMC Cardiovasc Disord

Department of Laboratory Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, No. 1 Shuaifu Yuan, Dongcheng District, Beijing, 100730, China.

Published: March 2025

Waldenström macroglobulinemia (WM) is a rare hematological disorder with an annual incidence of about 3 per million. Its clinical manifestations are diverse and non - specific, and approximately 30% of patients are asymptomatic, making early diagnosis challenging. This paper reports a 73-year-old female who was admitted to the hospital due to atrial fibrillation. During a physical examination several years before the hospitalization, an elevated CA19-9 was detected, but the cause remained unclear after multiple outpatient visits. During cardiac markers testing, an abnormal serum index (HIL) suggested a lipidemic sample, yet the sample appeared clear visually. A Sia water test showed positive result, and subsequent serum protein electrophoresis confirmed the presence of M protein, leading to the diagnosis of WM. During the treatment in the following 6 years, it was found that the levels of CA19-9 and IgM fluctuated in parallel. Abnormal lipid indices and albumin-globulin ratio can provide important clues for the diagnosis of WM, but they may be overlooked in clinical practice. When the total protein increases with normal or decreased albumin levels, a reflex test of serum protein electrophoresis can help with early diagnosis. This case shows that understanding and using interference information in laboratory tests can assist in the diagnosis of WM.

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12872-025-04588-wDOI Listing

Publication Analysis

Top Keywords

waldenström macroglobulinemia
8
early diagnosis
8
serum protein
8
protein electrophoresis
8
diagnosis
6
interference insight
4
insight pseudo-lipidemia
4
pseudo-lipidemia led
4
led diagnosis
4
diagnosis waldenström
4

Similar Publications

From interference to insight: pseudo-lipidemia led to the diagnosis of Waldenström macroglobulinemia.

BMC Cardiovasc Disord

March 2025

Department of Laboratory Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, No. 1 Shuaifu Yuan, Dongcheng District, Beijing, 100730, China.

Waldenström macroglobulinemia (WM) is a rare hematological disorder with an annual incidence of about 3 per million. Its clinical manifestations are diverse and non - specific, and approximately 30% of patients are asymptomatic, making early diagnosis challenging. This paper reports a 73-year-old female who was admitted to the hospital due to atrial fibrillation.

View Article and Find Full Text PDF

As the treatment paradigm for Waldenström macroglobulinemia (WM) continues to evolve, the debate surrounding the prioritization of depth of response versus disease control as therapeutic goals gains significant relevance. However, the impact of depth of response from fixed-duration therapy on overall survival (OS) was unclear. This multicenter study evaluated the prognostic impact of depth of response using a landmark survival analysis.

View Article and Find Full Text PDF

Purpose: Waldenström macroglobulinemia (WM) is a rare type of lymphoma, with no optimal treatment. BTK inhibitor have shown promising outcomes, yet achieving deep remission (VGPR or CR) remains challenging and time-limited therapy with proteasome-inhibition has not been reported. We conducted a phase 2 clinical trial (NCT04463953) to evaluate the efficacy and safety of combining zanubrutinib, ixazomib and dexamethasone (ZID) in newly diagnosed WM patients.

View Article and Find Full Text PDF

Optic Disc Edema as the Initial Presentation of Bing-Neel Syndrome.

Neuroophthalmology

August 2024

Optometry/Ophthalmology, Jamaica Plain VA Boston Healthcare System, Boston, Massachusetts, USA.

A 54-year-old man with a history of Waldenstrom's macroglobulinemia (WM) presented with sudden-onset blurred vision in the left eye. This case will demonstrate a unique presentation of unilateral optic disc edema that stems from a patient's medical history of WM leading to a rare diagnosis of Bing-Neel Syndrome.

View Article and Find Full Text PDF

From development to clinical success: the journey of established and next-generation BTK inhibitors.

Invest New Drugs

February 2025

Department of Pharmacology, Institute of Medical Science, Banaras Hindu University, Varanasi, 221005, India.

Over the past decade, Bruton's tyrosine kinase (BTK) has emerged as a pivotal therapeutic target for B-cell malignancies and autoimmune diseases, given its essential role in B-cell development and function. Dysregulation of BTK signalling is implicated in a range of hematologic cancers, including Waldenström's macroglobulinaemia (WM), mantle cell lymphoma (MCL), and chronic lymphocytic leukaemia (CLL). The development of BTK inhibitors (BTKIs), starting with ibrutinib, has revolutionized the treatment of these malignancies by inhibiting B-cell receptor (BCR) signalling and inducing apoptosis in malignant B-cells.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!